UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  February 22, 2011

Viropro, Inc.
(Exact Name of Registrant as Specified in its Charter)

     
Nevada
333-06718
13-3124057
(State or other jurisdiction of incorporation)
(Commission File  Number)
(IRS Employer Identification No.)

     
4199 Campus Drive
Suite 550
Irvine CA
 
92612
(Address of principal executive offices)
 
(Zip Code)

Registrant's telephone number, including area code: (949) 725-2969

N/A
(Former Name or Former Address if Changed Since Last Report)
1806-300 Avenue des Sommets, QC, H3E 2B7

Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]
Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
[  ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
[  ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



SEC 873  (5-06)
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 
 
 
 
ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

 
a)
February 22, 2011
  
 
b)
Through a Share Purchase Agreement, Viropro Inc acquires 100 % of  Alpha Biologics Sdn. Bhd. of Penang, Malaysia, a contract process development and GMP biomanufacturing company, with process development laboratories located in Cambridge, UK and a GMP mammalian cell clinical production facility located in the Penang Science Park.
  
 
c)
 
 
 
a.
Springhill Bioventures Sdn Bhd
 
b.
THG Capital Sdn Bhd
 
c.
Michelle Leanne Edythe Peake

 
d)
Viropro shall issue 525,000,000 restricted shares valued at US$0.04 each, representing a total value of US$21 million. The offer and sale of the shares was made pursuant to a non-US person pursuant to Rule 903(b)(3).
 


 
 
 

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Date: February 23, 2011

 

VIROPRO, INC.



/s/ Rajiv V. Datar

Rajiv V. Datar, President and Chief Executive Officer




Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Viropro (CE) Charts.
Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Viropro (CE) Charts.